CKI 7 dihydrochloride: Precision Casein Kinase 1 Inhibition for Signaling Pathway Research

Principle and Setup: Harnessing CKI 7 dihydrochloride for Targeted CK1 Modulation

CKI 7 dihydrochloride, also known by its chemical name N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide dihydrochloride, is a highly selective and potent Casein kinase 1 (CK1) inhibitor. CK1 is a serine/threonine kinase central to key cellular processes, including circadian rhythm regulation, Wnt signaling, DNA repair, and cell fate determination. Aberrant CK1 activity is implicated in diverse disease mechanisms, prominently cancer metastasis and circadian rhythm disorders. CKI 7 dihydrochloride—available from APExBIO—enables researchers to dissect CK1-dependent phosphorylation events with precision, thanks to its high aqueous (up to 7.17 mg/ml in water) and DMSO (up to 17.93 mg/ml) solubility and robust cell permeability.

As a cell-permeable CK1 inhibitor for signaling pathway research, CKI 7 dihydrochloride is widely deployed in workflows targeting the inhibition of CK1 in the Wnt signaling pathway, modulation of protein phosphorylation, apoptosis assays, and advanced cancer biology research. The stability of the compound is ensured by storage at -20°C, with freshly prepared solutions recommended for optimal activity. For those researching the molecular underpinnings of metastasis—such as modulation of the MAPK10/KRT16/RNF213 axis in non-small cell lung cancer (NSCLC)—CKI 7 dihydrochloride provides a powerful tool for pathway interrogation (Luo et al., 2026).

Step-by-Step Experimental Workflow: Enhancing Protocols with CKI 7 dihydrochloride

1. Preparation of Stock Solutions

• Dissolve CKI 7 dihydrochloride in DMSO (up to 17.93 mg/ml) or water (up to 7.17 mg/ml).
• Prepare aliquots to avoid repeated freeze-thaw cycles; store at -20°C.
• For cell-based applications, dilute the stock in culture medium to achieve final working concentrations (commonly 1–20 μM).

2. Application in Cell Culture and Biochemical Assays

• For Wnt signaling pathway modulation, treat cells (e.g., HEK293, NSCLC lines) with CKI 7 dihydrochloride prior to Wnt ligand stimulation to block CK1-mediated phosphorylation events.
• Apoptosis assay using CK1 inhibitors: Add CKI 7 dihydrochloride to cells 1–2 hours before exposure to apoptotic stimuli; assess caspase activation or annexin V staining.
• In protein phosphorylation inhibition studies, incubate cell lysates or in vitro kinase assays with CKI 7 dihydrochloride to block CK1-driven phosphorylation, then analyze by Western blot using phospho-specific antibodies.
• For circadian rhythm regulation studies, synchronize cells (e.g., NIH 3T3) and apply CKI 7 dihydrochloride to investigate effects on clock gene expression or period length.

3. Data Capture and Quantification

• Measure phosphorylation status, gene expression, or cell viability/proliferation using standard readouts (e.g., immunoblotting, qPCR, MTT/XTT assays).
• Include appropriate vehicle and positive controls to discriminate CK1-specific effects.

Advanced Applications and Comparative Advantages

CKI 7 dihydrochloride uniquely empowers researchers to modulate CK1 signaling with high specificity, offering several advantages for both basic and translational research:

• Dissecting CK1-Dependent Pathways in Cancer Biology: Recent breakthroughs, such as the study by Luo et al. (2026), have elucidated phosphorylation-dependent mechanisms controlling metastasis in NSCLC. CKI 7 dihydrochloride can be used to interrogate the role of CK1 in regulating the MAPK10/KRT16/RNF213 axis, providing insights into potential therapeutic targets and prognostic markers.
• Precision in Circadian Rhythm Modulation: The ability to selectively inhibit CK1 enables researchers to alter the phosphorylation of core clock proteins (e.g., PER/CRY), allowing for the investigation of circadian period, phase shifts, and amplitude changes—critical for understanding sleep disorders and metabolic diseases.
• Wnt Signaling and Developmental Biology: CKI 7 dihydrochloride inhibits CK1-mediated phosphorylation of key Wnt components (e.g., β-catenin), facilitating mechanistic studies of cell fate, differentiation, and tumorigenesis.

For comparative analysis, the article “CKI 7 Dihydrochloride: Precision Casein Kinase 1 Inhibition” explores the translational strategy of targeting CK1 for both mechanistic and therapeutic goals, acting as an extension of the current discussion by integrating MAPK10/KRT16 axis research. In contrast, “CKI 7 dihydrochloride (SKU B4936): Reliable CK1 Inhibition” provides practical Q&A and robust workflow scenarios, complementing this article’s protocol-driven approach. Meanwhile, “CKI 7 dihydrochloride: Selective Casein Kinase 1 Inhibitor” consolidates peer-reviewed benchmarks to ensure reproducibility, reinforcing the reliability of APExBIO’s product.

Quantitative performance details: CKI 7 dihydrochloride demonstrates IC₅₀ values in the low micromolar range against CK1 isoforms, with minimal off-target activity reported in peer-reviewed assays (source). In cell-based experiments, effective pathway inhibition is observed at 5–10 μM, with no significant cytotoxicity at these concentrations in most cell lines.

Troubleshooting & Optimization: Maximizing Data Quality with CKI 7 dihydrochloride

• Solubility Concerns: CKI 7 dihydrochloride is highly soluble in DMSO and water, but precipitation can occur at high concentrations or upon dilution into cold media. Warm solutions to room temperature and vortex thoroughly before use.
• Compound Stability: Prepare fresh working solutions immediately before experiments. Long-term storage of diluted solutions is not recommended, as compound degradation can impact activity.
• Vehicle Effects: Always include DMSO-only controls, especially in sensitive cell lines, to attribute observed effects specifically to CKI 7 dihydrochloride.
• CK1 Isoform-Specific Effects: CKI 7 dihydrochloride targets multiple CK1 isoforms (e.g., CK1α, δ, ε). Use genetic validation (CRISPR, shRNA) in parallel to confirm isoform-specific outcomes.
• Assay Sensitivity: When quantifying protein phosphorylation inhibition, use phospho-specific antibodies validated for your target residues. For apoptosis or viability assays, ensure appropriate dynamic range and replicate number for statistical power.
• Batch Consistency: Source CKI 7 dihydrochloride from a trusted supplier like APExBIO to guarantee reproducibility; batch-to-batch variability can compromise longitudinal studies.

Future Outlook: Expanding the Frontiers of CK1 Signaling Research

The landscape of CK1 signaling pathway modulation is rapidly evolving, with CKI 7 dihydrochloride at the forefront of both mechanistic discovery and translational application. As studies continue to unravel the interplay between CK1, MAPK, and ubiquitination axes in tumor progression and circadian biology, this inhibitor is poised to facilitate breakthroughs in biomarker discovery and personalized therapy development. Emerging high-throughput assays, single-cell phosphoproteomics, and CRISPR-based screens are expected to synergize with CKI 7 dihydrochloride-driven workflows, enabling a systems-level understanding of CK1’s diverse roles.

For researchers seeking a reliable, well-characterized Casein kinase 1 inhibitor, CKI 7 dihydrochloride from APExBIO remains the gold standard for both foundational and advanced signaling pathway studies. With its proven utility across cancer biology research, circadian rhythm regulation studies, and cutting-edge protein phosphorylation inhibition, CKI 7 dihydrochloride is an indispensable tool for the next generation of biomedical discovery.